Hiroyuki Saitou, Taichi Kitaoka, Takuo Kubota, Junko Kanno, Hiroshi Mochizuki, Toshimi Michigami, Kosei Hasegawa, Ikuma Fujiwara, Takashi Hamajima, Daisuke Harada, Yuko Seki, Keisuke Nagasaki, Sumito Dateki, Noriyuki Namba, Hirofumi Tokuoka, Jeanne M Pimenta, Shelda Cohen, Keiichi Ozono
Achondroplasia (ACH) is a rare, autosomal dominant skeletal dysplasia characterized by short stature, characteristic facial configuration, and trident hands. Before vosoritide approval in Japan, patients with ACH could start growth hormone (GH) treatment at age 3 years. However, ACH and its treatment in young Japanese children have not been studied. This retrospective, longitudinal, medical records-based cohort study (before vosoritide approval) summarized symptoms, complications, monitoring, surgery/interventions, and height with/without GH in Japanese patients with ACH <5 years...
March 30, 2024: American Journal of Medical Genetics. Part A